A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.

Novel Agents in the Treatment of Lung Cancer:
Advances in EGFR Inhibitors

A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.

InforMEDical Communications, Inc. • 83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com

Introduction

EGFR Oncogene Addiction and Resistance in Lung Cancer

Erlotinib (Tarceva®) 2008: Role in Lung Cancer Therapy

T790M: Understanding Its Role in Resistance and Potential as a Therapeutic Target

The Role of MET Amplification in EGFR Resistance

Modeling Genotype-Associated Sensitivity to Receptor Tyrosine Kinase Inhibitors in Lung Cancer-Derived Cell Lines

Novel Irreversible EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Heat Shock Protein 90: An Emerging Target for Anticancer Therapy

MTOR Inhibitors

Emerging Role of Cetuximab in Advanced Non-Small Lung Cancer

The Use of Biomarkers to Guide Cetuximab Therapy

Integrating EGFR Blockade Into Combined-Modality Therapy for Non-Small Cell Lung Cancer

Guidelines for the Practicing Clinician: EGFR-Based Therapies In 2008

References